Thus, in ERG-positive high-grade tumors (Gleason greater than 4+3) [42,43,44], expressing a high level of LINC02418, the MELK inhibitor OTS167 could be a promising therapeutic opportunity, because it is already utilized in clinical trials for the treatment of breast cancer and onco-hematological pathologies [45]. Here, ERG is linked to breast cancer.